Nguyen, Ryan Y. http://orcid.org/0000-0002-5001-7893
Xiao, Hugh
Gong, Xiangyu http://orcid.org/0000-0003-4033-9570
Arroyo, Alfredo
Cabral, Aidan T.
Fischer, Tom T. http://orcid.org/0000-0002-2138-9102
Flores, Kaitlin M.
Zhang, Xuchen
Robert, Marie E.
Ehrlich, Barbara E. http://orcid.org/0000-0001-9657-9704
Mak, Michael http://orcid.org/0000-0001-6881-8130
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM142875)
Article History
Received: 13 August 2021
Accepted: 8 February 2022
First Online: 3 March 2022
Competing interests
: The authors declare the following competing interests: B.E.E. is a cofounder of Osmol Therapeutics, a company that is targeting NCS1 for therapeutic purposes. The remaining authors declare no competing interests.